Monitoring bcr-abl by polymerase chain reaction in the treatment of chronic myeloid leukemia

Current Oncology Reports

Volumn 5, Issue 5, 2003, Pages 426-435

  Oehler, Vivian G ^a   Radich, Jerald P ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; DNA; FLUORESCENT DYE; IMATINIB; INTERFERON; MESSENGER RNA; NUCLEIC ACID; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ALLOTRANSPLANTATION; ANALYTICAL EQUIPMENT; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DNA PROBE; DONOR; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; LEUKEMIA REMISSION; LEUKEMOGENESIS; LYMPHOCYTE TRANSFUSION; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MINIMAL RESIDUAL DISEASE; PATHOLOGY; PATIENT MONITORING; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; PREDICTION; RELAPSE; REVIEW; TREATMENT PLANNING; METABOLISM; MONITORING; RECURRENT DISEASE;

BONE MARROW TRANSPLANTATION; FUSION PROTEINS, BCR-ABL; HUMANS; INTERFERONS; LEUKEMIA, MYELOID, CHRONIC; MONITORING, PHYSIOLOGIC; NEOPLASM, RESIDUAL; PHILADELPHIA CHROMOSOME; PIPERAZINES; POLYMERASE CHAIN REACTION; PYRIMIDINES; RECURRENCE;

EID: 2142802114     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-003-0030-x     Document Type: Review

References (77)

1. Hansen JA, Gooley TA, Martin PJ, et al.: Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998, 338:962-968.
2. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
3. Druker BJ, O'Brien SG, Cortes J: Chronic myelogenous leukemia. In American Society for Hematology Education Book. Washington, DC: ASH; 2002:111-135.
4. Talpaz M, Silver RT, Druker BJ, et al.: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002, 99:1928-1937.
5. Sawyers CL, Hochhaus A, Feldman E, et al.: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002, 99:3530-3539.
6. Diamond J, Goldman JM, Melo J V: BCR-ABL, ABL-BCR, BCR, and ABL genes are all expressed in individual granulocyte-macrophage colony-forming unit colonies derived from blood of patients with chronic myeloid leukemia. Blood 1995, 85:2171-2175.
7. Melo JV: The molecular biology of chronic myeloid leukaemia. Leukemia 1996, 10:751-756.
8. Shepherd P, Suffolk R, Halsey J, Allan N: Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br J Haematol 1995, 89:546-554.
9. Faderl S, Talpaz M, Estrov Z, et al.: The biology of chronic myeloid leukemia. N Engl J Med 1999, 341:164-172.
10. Hermans A, Heisterkamp N, von Linden M, et al.: Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell 1987, 51:33-40.
11. Hochhaus A, Reiter A, Skladny H et al.: A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia. Blood 1996, 88:2236-2240.
12. van der Plas DC, Soekarman D, van Gent AM, et al.: bcr-abl mRNA lacking abl exon a2 detected by polymerase chain reaction in a chronic myelogeneous leukemia patient. Leukemia 1991, 5:457-461.
13. Wang JY: Regulation of cell death by the Abl tyrosine kinase. Oncogene 2000, 19:5643-56450.
14. Ben-Neriah Y, Daley GQ, Mes-Masson AM, et al.: The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 1986, 233:212-214.
15. Deininger MWN, Goldman JM, Melo JV: The molecular biology of chronic myeloid leukemia. Blood 2000, 96:3343-3356.
16. Hook EB: Exclusion of chromosomal mosaicism: tables of 90%, 95% and 99% confidence limits and comments on use. Am J Hum Genet 1977, 29:94-97.
17. Arthur CK, Apperley JF, Guo AP, et al.: Cytogenetic events after bone marrow transplantation for chronic myeloid leukemia in chronic phase. Blood 1988, 71:1179-1186.
18. Huntly BJ, Reid AG, Bench AJ, et al.: Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001, 98:1732-1738.
19. Sinclair PB, Nacheva EP, Leversha M, et al.: Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000, 95:738-743.
20. Seong DC, Kantarjian HM, Ro JY, et al.: Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood 1995, 86:2343-2349.
21. Nylund SJ, Ruutu T, Saarinen U, Knuutila S: Metaphase fluorescence in situ hybridization (FISH) in the follow-up of 60 patients with haemopoietic malignancies. Br J Haematol 1994, 88:778-783.
22. Bernell P, Arvidsson I, Jacobsson B, Hast R: Fluorescence in situ hybridization in combination with morphology detects minimal residual disease in remission and heralds relapse in acute leukaemia. Br J Haematol 1996, 95:666-672.
23. Engel H, Drach J, Keyhani A, Jiang S, et al.: Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells. Leukemia 1999, 13:568-577.
24. Cotteret S, Belloc F, Boiron JM, et al.: Fluorescent in situ hybridization on flow-sorted cells as a tool for evaluating minimal residual disease or chimerism after allogenic bone marrow transplantation. Cytometry 1998, 34:216-222.
25. Slovak ML, Zhang F, Tcheurekdjian L, et al.: Targeting multiple genetic aberrations in isolated tumor cells by spectral fluorescence in situ hybridization. Cancer Detect Prev 2002, 26:171-179.
26. Heid CA, Stevens J, Livak KJ, Williams PM: Real time quantitative PCR. Genome Res 1996, 6:986-994.
27. Radich JP, Gehly G, Gooley T, et al.: Polymerase chain reaction detection of BCR/ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995, 85:2632-2638.
28. Radich JP, Gooloey T, Bryant E, et al.: The significance of bcr-abl molecular detection in chronic myeloid leukemia patients 'late', 18 months or more after transplantation. Blood 2001, 98:1701-1707.
29. Emig M, Saussele S, Wittor H, et al.: Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999, 13:1825-1832.
30. Roth MS, Antin JH, Ash R, et al.: Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. Blood 1992, 79:276-282.
31. Miyamura K, Tahara T, Tanimoto M, et al.: Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: a study of 64 patients. Blood 1993, 81:1089-1093.
32. Cross NC: Minimal residual disease in chronic myeloid leukaemia. Hematol Cell Ther 1998, 40:224-228.
33. el-Rifai W, Ruutu T, Vettenranta K, et al.: Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia: a metaphase-FISH study. Br J Haematol 1996, 92:365-369.
34. Hughes TP, Morgan GJ, Martiat P, Goldman JM: Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood 1991, 77:874-878.
35. Mughal TI, Yong A, Szydlo RM, et al.: Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. Br J Haematol 2001, 115:569-574.
36. Pichert G, Roy D-C, Gonin R, et al.: Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol 1995, 13:1704-1713.
37. Costello RT, Kirk J, Gabert J: Value of PCR analysis for long term survivors after allogeneic bone marrow transplant for chronic myelogenous leukemia: a comparative study. Leuk Lymphoma 1996, 20:239-242.
38. van Rhee F, Cross NCP, Reid CDL, et al.: Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukemia. Bone Marrow Transplant 1994, 14:609-612.
39. McSweeney PA, Niederwieser D, Shizuru JA, et al.: Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001, 97:3390-3400.
40. Mackinnon S, Barnett L, Heller G: Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 1996, 17:643-647.
41. Lin F, van Rhee F, Goldman JM, Cross NCP: Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 1996, 87:4473-4478.
42. Mensink E, van de Locht A, Schattenberg A, et al.: Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukemia patients using real-time quantitative RT-PCR. Br J Haematol 1998, 102:768-774.
43. Preudhomme C, Chams-Eddine L, Roumier C, et al.: Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using an in situ RT-PCR assay. Leukemia 1999, 13:818-823.
44. Olavarria E, Kanfer E, Szydlo R, et al.: Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001, 97:1560-1565.
45. Branford S, Hughes TP, Rudzki Z: Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 1999, 107:587-599.
46. Sawyers CL, Timson L, Kawasaki ES, et al.: Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction. Proc Natl Acad Sci U S A 1990, 87:563-567.
47. Deininger M, Lehmann T, Krahl R, et al.: No evidence for persistence of BCR-ABL-positive cells in patients in molecular remission after conventional allogenic transplantation for chronic myeloid leukemia. Blood 2000, 96:779-780.
48. Chase A, Parker S, Kaeda J, et al.: Absence of host-derived cells in the blood of patients in remission after allografting for chronic myeloid leukemia. Blood 2000, 96:777-778.
49. Chomel JC, Brizard F, Veinstein A, et al.: Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation. Blood 2000, 95:404-409.
50. Zhang JG, Goldman JM, Cross NC: Characterization of genomic BCR-ABL breakpoints in chronic myeloid leukaemia by PCR. Br J Haematol 1995, 90:138-146.
51. Zhang JG, Lin F, Chase A, et al.: Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation. Blood 1996, 87:2588-2593.
52. Kantarjian HM, O'Brien S, Cortes J, et al.: Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003, 97:1033-1041.
53. Hochhaus A, Lin F, Reiter A, et al.: Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 1996, 87:1549-1555.
54. Hochhaus A, Lin F, Reiter A, et al.: Monitoring the efficiency of interferon-alpha therapy in chronic myelogenous leukemia (CML) patients by competitive polymerase chain reaction. Leukemia 1997, 11(Suppl 3):541-544.
55. Kurzrock R, Estrov Z, Kantarjian H, Talpaz M: Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol 1998, 16:1526-1531.
56. Hochhaus A, Lin F, Reiter A, et al.: Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha. Br J Haematol 1995, 91:126-131.
57. Hughes T, Kaeda J, Branford S, et al.: Molecular responses to imatinib: (STI571) or interferon + Ara-C as initial therapy for CML: results in the IRIS study. Blood 2002, 100:93a-94a.
58. Kantarjian HM, Talpaz M, O'Brien S, et al.: Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res 2002, 8:2177-2187.
59. Merx K, Muller MC, Kreil S, et al.: Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 2002, 16:1579-1583.
60. Wu CJ, Neuberg D, Chillemi A, et al.: Quantitative monitoring of BCR/ABL transcript during STI-571 therapy. Leuk Lymphoma 2002, 43:2281-2289.
61. Bumm T, Muller C, Al-Ali HK, et al.: Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003, 101:1941-1949.
62. O'Dwyer ME, Gatter KM, Loriaux M, et al.: Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 2003, 17:481-487.
63. Kwok S, Higuchi R: Avoiding false positives with PCR. Nature 1989, 339:237-238.
64. Miyamoto T, Nagafuji K, Akashi K, et al.: Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood 1996, 87:4789-4796.
65. Tobal K, Saunders MJ, Grey MR, Yin JA: Persistence of RAR alpha-PML fusion mRNA detected by reverse transcriptase polymerase chain reaction in patients in long-term remission of acute promyelocytic leukaemia. Br J Haematol 1995, 90:615-608.
66. Bose S, Deininger M, Gora-Tybor J, et al.: The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessement of minimal residual disease. Blood 1998, 92:3362-3367.
67. Radich JP: The detection and significance of minimal residual disease in chronic myeloid leukemia. Medicina (B Aires) 2000, 60:66-70.
68. Vora A, Frost L, Goodeve A, et al.: Late relapsing childhood lymphoblastic leukemia. Blood 1998, 92:2334-2337.
69. Nitta M, Kato Y, Strife A, et al.: Incidence of involvement of the B and T lymphocyte lineages in chronic myelogenous leukemia. Blood 1985, 66:1053-1061.
70. Kearney L, Orchard KH, Hibbin J, Goldman JM: T-cell cytogenetics in chronic granulocytic leukaemia. Lancet 1982, 1:858.
71. Vickers M: Estimation of the number of mutations necessary to cause chronic myeloid leukaemia from epidemiological data. Br J Haematol 1996, 94:1-4.
72. Lin F, Goldman JM, Cross NC: A comparison of the sensitivity of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukemia. Br J Haematol 1994, 89:684-685.
73. Buno I, Wyatt WA, Zinsmeister AR, et al.: A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia. Blood 1998, 92:2315-2321.
74. Le Gouill S, Talmant F, Milpied N, et al.: Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia. J Clin Oncol 2000, 18:1533-1538.
75. Muhlmann J, Thaler J, Hilbe W, et al.: Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment. Genes Chromosomes Cancer 1998, 21:90-100.
76. Chen Z, Notohamiprodjo M, Richards PD, et al.: Some observations on fluorescence in situ hybridization evaluation of chronic myelocytic leukemia. Cancer Genet Cytogenet 1997, 98:1-3.
77. Akel S, Kolialexi A, Mavrou A, et al.: Efficiency of interphase fluorescence in situ hybridization for BCR/ABL on peripheral blood smears for monitoring of CML patients: a comparison with bone marrow findings. Clin Lab Haematol 2002, 24:361-367.